<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970851</url>
  </required_header>
  <id_info>
    <org_study_id>08/12</org_study_id>
    <nct_id>NCT02970851</nct_id>
  </id_info>
  <brief_title>Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb) Positron Emission Tomography/Computed Tomography (PET/CTs) on Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</brief_title>
  <official_title>Effect of Endothelin Receptor Antagonist Bosentan in Glucose Metabolism of the Myocardium and Coronary Dependant Endothelial Vasoreactivity Measured by 18F-FDG PET / CT and 82Rb PET / CT in Patients With PAH or CTEPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of bosentan on the myocardial metabolism
      and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.

      Hypothesis : Bosentan may improve right ventricular function by decreasing myocardial stress
      and glucose metabolism. Patients may benefit from images with 18F-FDG PET / CT and 82Rb PET /
      CT for an earlier assessment and optimal management of PAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients refered to the hospital for a right heart catheterization for a PAH suspected at the
      echocardiography will be presented with the protocol.If inclusion/exclusion criteria are
      fulfilled all the procedures will be planned. At the screening visit the patient will have a
      right heart catheterization and an echocardiography. After a maximum of 4 weeks each patient
      will have 18F-FDG and 82Rb PET/CTs before start of treatment with Bosentan. These PET/CTs
      together with an echocardiography will be repeated at 6 and 12 weeks after start of treatment
      with bosentan.

      Finally a right heart catheterization will be planned at 12 weeks after start of treatment
      with bosentan as a routine procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>Baseline</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial ventricular right maximum standardized uptake value (SUVmax) on the images of au 18F-FDG PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular right maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT rest MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT stress MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at pharmacological stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>Baseline</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On the images 82Rb PET/CT, analysis of endothelial dysfunction cold test MBF</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>myocardial blood flow (MBF in mL/min/g) at cold test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>Baseline</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 4 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 6 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of each method of imaging for assessment of myocardial metabolism and endothelial dysfunction</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>On the images of au 18F-FDG PET/CT : myocardial ventricular left maximum standardized uptake value (SUVmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PAP</measure>
    <time_frame>at screening</time_frame>
    <description>pulmonary arterial pressure (PAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PAP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>PAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters RAP</measure>
    <time_frame>at screening</time_frame>
    <description>right atrial pressure (RAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters RAP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>RAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PWP</measure>
    <time_frame>at screening</time_frame>
    <description>pulmonary wedge pressure (PWP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of right heart catheterization parameters PWP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>PWP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NYHA</measure>
    <time_frame>at screening</time_frame>
    <description>NYHA classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NYHA</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>New York Heart Association (NYHA) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters 6-min walk test</measure>
    <time_frame>at screening</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters 6-min walk test</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters LFT</measure>
    <time_frame>at screening</time_frame>
    <description>Results of lung function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters LFT</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>Results of lung function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NT-pro-BNP</measure>
    <time_frame>at screening</time_frame>
    <description>plasmatic N terminal - pro - Brain Natriuretic Peptide (NT-pro-BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of clinical parameters NT-pro-BNP</measure>
    <time_frame>at 12 weeks after start of treatment</time_frame>
    <description>plasmatic NT-pro-BNP</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myocardial Dysfunction</condition>
  <condition>Endothelial Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for Bosentan therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic PAH (PH group 1 Dana Point / stages 2 à 4 according to NYHA
             classification, defined by a mean arterial pulmonary pressure &gt;25 millimeter of
             mercury (mmHg) at rest, an occlusion arterial pulmonary pressure &lt;15 millimeter of
             mercury (mmHg) and vascular pulmonary resistance &gt;240 dyn.s.cm-5 for which a treatment
             with bosentan is indicated Or Patients with CTEPH not candidate for a pulmonary
             endarterectomy or patient with residual CTEPH after pulmonary endarterectomy (PH group
             4 Dana Point / stages 2 to 4 according to NYHA classification) and for which a
             treatment with bosentan is indicated

          -  Indication to perform a right heart catheterization in the context of PAH suspected
             during cardiac ultrasound

          -  Age from 18 to 80 years old, male and female

          -  Karnofsky index ≥80%

          -  Informed consent signed

        Exclusion Criteria:

          -  Patients with PAH stages 2,3 or 5 of Dana Point

          -  Patients with a contra-indication to adenosine including severe uncontrolled asthma,
             severe uncontrolled chronic obstructive pulmonary disease, 2nd or 3rd degree
             atrioventricular block without pacemaker,

          -  Patients with a contraindication to Bosentan, i.e :hypersensibility to the product,
             hepatic failure Child Pugh B or C, aminotransferases &gt;3 times normal value
             (N),association with cyclosporine A or glibenclamide

          -  Pregnancy, female of child-bearing potential not using any acceptable contraceptive
             method, breastfeeding

          -  Atrial fibrillation (Ventricular Ejection Fraction (VEF) not evaluable at echography)

          -  Karnofsky index &lt;80%

          -  Impossibility to obtain informed consent signed

          -  Left cardiopathies that can be responsible of post-capillar hypertension

          -  Involvement in another clinical study with an unregistered drug within 30 days prior
             to this specific study and during the entire course of the study

          -  Inability to comply with study procedures (linguistic problem, psychiatric problems,
             dementia, confusional state)

          -  Known or suspected non compliance drug or alcohol abuse

          -  Left heart assessment : diastolic and systolic function and valvular structures to
             exclude a cardiac pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O Prior, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John O Prior, MD,PhD</last_name>
    <phone>+41 21 314 43 48</phone>
    <email>john.prior@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Geldhof</last_name>
    <phone>+41213144346</phone>
    <email>christine.geldhof@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>John O. Prior</investigator_full_name>
    <investigator_title>Chief of the Department of Nuclear medicine</investigator_title>
  </responsible_party>
  <keyword>Endothelin receptor antagonist (ERA)</keyword>
  <keyword>pulmonary artery hypertension (PAH),</keyword>
  <keyword>18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT)</keyword>
  <keyword>Rubidium-82 (82Rb) PET/CT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
    <mesh_term>Deoxyglucose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

